Nippon Shinyaku Obtains Higher Than Estimated Price For Vidaza
This article was originally published in PharmAsia News
Executive Summary
Nippon Shinyaku obtained a price listing for myelodysplastic syndromes drug Vidaza (azacitidine), and the price of ¥49,993 for 100 mg injection exceeded what Citi analysts had estimated